-
February 1, 2021
The Third Quarter of FY2020 (April 2020- December 2020) -
February 1, 2021
R&D Pipeline as of February 2021 -
November 13, 2020
Annual Report 2020 -
November 5, 2020
The Second Quarter of FY2020 (April 2020 - September 2020) -
August 3, 2020
The First Quarter of FY2020 (April 2020 - June 2020)
-
March 24, 2021
Participation in global Phase III clinical trial for CG0070, a drug for bladder cancer -
March 1, 2021
Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Receptor Inhibitor, in Japan -
January 13, 2021
Results of Phase III Clinical Study of AJM300 (Nonproprietary Name: Carotegrast Methyl) for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/CT3 Study) - Primary Endpoint Achieved - -
December 10, 2020
The Efficacy and Safety Results of the Overseas Phase-III Long-Term Study of Uterine Fibroids for GnRH Antagonist, Linzagolix, conducted by ObsEva -
November 24, 2020
Submission of Marketing Authorization Application to the European Medicines Agency for Linzagolix for the treatment of uterine fibroids
